NEW YORK (GenomeWeb News) – Agilent Technologies has appointed Robert Schueren to be VP and GM of Genomics, and John Fjeldsted to be GM of Liquid Chromatrography/ Mass Spectrometry. George Stafford, who recently was responsible for LC/MS at Thermo Fisher Scientific, has joined the company as LC/MS hardware R&D manager.
Schueren formerly was global head of companion diagnostics, clinical biomarkers, and sample operations at Genentech/Roche. Fjeldsted has been at Agilent for more than 25 years, and he recently was R&D manager for LC/MS.
Beckman Coulter's board of directors has approved a cash bonus of $150,000 for Chairman, President and CEO Scott Garrett, according to a filing with the US Securities and Exchange Commission. The board said that the one-time special bonus is a recognition of Garrett's efforts in connection with the company's acquisition and integration of the diagnostics business of Olympus.
PrognosDx Health has appointed Daniel Hunt to serve as acting senior VP of corporate development. Hunt formerly was general counsel of licensing, contracts management, and patent law at Genentech, and he was director of legal affairs at Abgenix. He also has been chief corporate counsel at Roche Molecular Systems, where he was responsible for business development and transactional support, and he managed Roche's PCR licensing program.
Genomic engineering company Evolugate has tapped Russell Howard and Terrance Bruggeman to sit on its advisory board. Howard currently is CEO of Oakbio, and for 11 years he was CEO of Maxygen. Bruggeman currently is executive chairman of BioTork, a recently-created spin-off firm aimed at the biofuels market. Evolugate's technology enables the evolution of microorganisms used in a range of industrial applications, or "microbial evolution on demand," as Howard called it in a statement.
Vermillion this week announced the re-appointment of Gail Page as CEO, and it has re-appointed Eric Fung as senior VP and CSO, both effective immediately.
The appointments are part of a reorganization that follows the company's emergence from Chapter 11 bankruptcy last month.
The firm's previous appointment of William Wallen to its board of directors is now effective, and John Tran was appointed interim vice president of finance and chief accounting officer.
Page, who will receive a base salary of $375,000, has been with Vermillion as president since 2004, and she has been CEO since 2005. Fung, who will be paid a base salary of $275,000, has been with the company since 2000 as a lead scientist in the Biomarker Discovery Centers.
Harvard Medical School said this week that it has appointed William Chin to be executive dean for research, a new position with overarching responsibility for biomedical research at HMS. Chin comes to the post form his job as senior VP for discovery research and clinical investigation at Eli Lilly and Company.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.